Targeting NLRP1 ‐ CCL8 axis in the leukaemic niche suppresses AML via inhibition of PI3K ‐ AKT signalling
British Journal of Haematology · 2025
DOI: 10.1111/bjh.70011 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2025. Verfasst von Xingyue Li und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Proto-Oncogene Proteins c-akt, Signal Transduction, Phosphatidylinositol 3-Kinases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: Jiangsu Provincial Key Research and Development Program, National Natural Science Foundation of China, National Key Research and Development Program of China.
Abstract (Originalsprache)
Bone marrow microenvironment not only plays a key role in supporting normal haematopoiesis but also plays an important role in regulating the progression of acute myelogenous leukaemia (AML). Targeting the bone marrow microenvironment will provide new targets for AML treatment. However, until now, the mechanism by which the bone marrow microenvironment promotes AML progression remains obscure. Our previous studies have found that the bone marrow microenvironment Nucleotide‐binding Oligomerization Domain (NOD)‐Leucine Rich Repeat (LRR)‐containing Receptors (NLR) family pyrin domain containing 1 (NLRP1) plays an important role in the regulation of bone marrow endothelial cells, mesenchymal stem cell (MSC) cells and haematopoiesis, but the effect of the bone marrow microenvironment NLRP1 on AML has not been addressed. In this study, we found that niche Nlrp1 KO inhibited AML disease progression and leukaemia stem cell activity. Moreover, Nlrp1 was expressed in the bone marrow microenvironment, especially in MSC. Nlrp1 knockout in MSC inhibits the growth and proliferation of co‐cultured leukaemia cells, which is related to Nlrp1 KO inhibition of Ccl8 secretion in MSC and CCL8/CCR1‐mediated PI3K‐AKT activation in AML cells. Our study highlights the critical role of niche NLRP1 in AML and it could be a therapeutic target for AML.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
- Key Laboratory of Bone Marrow Stem Cells, Xuzhou, Jiangsu Province, China.
- Blood Diseases Institute, Xuzhou Medical University, Xuzhou, China.
- Xuzhou Ruihu Health Management Consulting Co., Ltd, Xuzhou, China.
- School of Medical Technology, Xuzhou Medical University, Xuzhou, China.
ORCID-Profile: Kailin Xu, Jianlin Qiao, Lingyu Zeng
Förderung
- Jiangsu Provincial Key Research and Development Program
- National Natural Science Foundation of China
- National Key Research and Development Program of China
- Major Basic Research Project of the Natural Science Foundation of the Jiangsu Higher Education Institutions
- Jiangsu Province High-Level Hospital Construction Project
Zitieren
APA
Li, X., Zhou, Q., Hao, X., Cao, C., Adzraku, S. Y., Song, X., Sun, C., Guo, X., Li, Y., Yuan, S., Huang, Y., Xu, K., Qiao, J., Zeng, L., & Ju, W. (2025). Targeting NLRP1 ‐ CCL8 axis in the leukaemic niche suppresses AML via inhibition of PI3K ‐ AKT signalling. British Journal of Haematology. https://doi.org/10.1111/bjh.70011
Vancouver
Li X, Zhou Q, Hao X, Cao C, Adzraku SY, Song X, et al. Targeting NLRP1 ‐ CCL8 axis in the leukaemic niche suppresses AML via inhibition of PI3K ‐ AKT signalling. British Journal of Haematology. 2025. doi:10.1111/bjh.70011
BibTeX
@article{Li2025,
author = {Li, Xingyue and Zhou, Qi and Hao, Xiaowen and Cao, Can and Adzraku, Seyram Yao and Song, Xuguang and Sun, Cai and Guo, Xiaofeng and Li, Yue and Yuan, Shengnan and Huang, Yujin and Xu, Kailin and Qiao, Jianlin and Zeng, Lingyu and Ju, Wen},
title = {Targeting NLRP1 ‐ CCL8 axis in the leukaemic niche suppresses AML via inhibition of PI3K ‐ AKT signalling},
journal = {British Journal of Haematology},
year = {2025},
doi = {10.1111/bjh.70011}
}
EUVIMED